George Health Enterprises and its subsidiary George Medicines have raised a combined $35m in funding from investors including Bupa Australia to drive pipeline development and commercialisation.

George Health Enterprises, the UK-based commercial arm of George Institute for Global Health operating an integrated healthcare business, secured £27m ($35m) in funding yesterday from investors including health insurance provider Bupa Australia.

The capital is split into a $22m investment in George Health that was co-led by Bupa Australia and private equity fund Federation Asset Management, and $13m for George Medicines that was supplied by Medical Research Commercialisation Fund (MRCF).

MRCF, backed by the government of Australia and managed by…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?